Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR

Chronic hepatitis C virus (HCV) is common. Treatment with direct acting antivirals (DAA) result in high sustained virologic response (SVR) associated with normalization of alanine aminotransferase (ALT). However, abnormal ALT after SVR has been observed. Since fatty liver disease can co‐exist with HCV, its impact on abnormal ALT after SVR is unknown. This was a retrospective case–control analysis evaluating those with SVR and baseline fatty liver disease by transient elastography defined by controlled attenuated parameter (CAP) was performed. Abnormal ALT was defined as >1.5 ULN. The primary analysis compared abnormal ALT at SVR‐12 and beyond in those with and without fatty liver disease. Six‐hundred and ninety‐three patients with SVR‐12 were evaluated. Abnormal ALT at SVR‐12 was present in 8.2% and was similar in those with and without fatty liver disease. Abnormal ALT at SVR‐12 was associated with atrial fibrillation (p = .02), CAP (p = .047), age (p = .08), baseline ALT (p = .008), BMI (p = .002) and obesity (p = .02). On multivariate analysis, only BMI was associated with abnormal ALT at SVR‐12 (p = .017). ALT at follow‐up after SVR‐12 was available in 264 patients. In those with initial normal ALT (n = 244), 11.5% had a delayed abnormal ALT and in those with initial abnormal ALT (n = 20), 47% remained abnormal while 53% normalized. Abnormal ALT after SVR following treatment with DAA is uncommon and related to increased BMI, but not related to underlying fatty liver disease assessed by CAP. The pattern of ALT can vary, and long‐term follow‐up is needed to assess the clinical impact of abnormal ALT after SVR.